|
Re: Herceptin results from the two key North American trials revisited--benefit holds
Somehow I am not as excited about a DFS of 73% and overall survival as 84%.
As grateful as I am to have received Herceptin, I'm really, really glad for Tykerb, Perjeta and Kadcyla too.
This is why I get so excited about the numbers on the vaccine trials. Those look even better to me.
Herceptin got the ball rolling on our Her2 research. If the folks hadn't gotten behind this treatment and advanced it to the market many more of us would be posting about recurrence and looking for 'magic unicorns'.
I am really looking forward to how our numbers improve over the next couple decades.
We've come a long way baby!
|
Threaded Mode